Published in Medical Letter on the CDC and FDA, August 10th, 2008
Jim DeMesa, M.D., President & CEO of MIGENIX stated, "The recent end of our 2008 fiscal year marks the beginning of a year where we expect to see the results of our efforts to date start to emerge. With Phase III clinical results, additional partnering prospects, and important program advancements - all expected in Fiscal 2009, we have several opportunities with which to create value. Most importantly, with an Omigard Phase III clinical trial milestone coming...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.